MX2014002214A - Uso del peptido activador de la adelinato ciclasa de pituitaria como adyuvante molecular para vacunas. - Google Patents

Uso del peptido activador de la adelinato ciclasa de pituitaria como adyuvante molecular para vacunas.

Info

Publication number
MX2014002214A
MX2014002214A MX2014002214A MX2014002214A MX2014002214A MX 2014002214 A MX2014002214 A MX 2014002214A MX 2014002214 A MX2014002214 A MX 2014002214A MX 2014002214 A MX2014002214 A MX 2014002214A MX 2014002214 A MX2014002214 A MX 2014002214A
Authority
MX
Mexico
Prior art keywords
pacap
vaccines
adjuvant
aquatic organisms
molecular adjuvant
Prior art date
Application number
MX2014002214A
Other languages
English (en)
Other versions
MX351725B (es
Inventor
García Mario Pablo Estrada
González Yamila Carpio
González Juana María Lugo
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of MX2014002214A publication Critical patent/MX2014002214A/es
Publication of MX351725B publication Critical patent/MX351725B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0003Invertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/0208Specific bacteria not otherwise provided for
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/205Rhabdoviridae, e.g. rabies virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/04Chelating agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/10011Birnaviridae
    • C12N2720/10034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/20011Rhabdoviridae
    • C12N2760/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24311Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con el uso del péptido activador de la adenilato ciclasa de pituitaria (PACAP) como adyuvante molecular para vacunas; entre otras aplicaciones, dichas vacunas pueden emplearse en la protección contra agentes infecciosos, tales como virus, bacterias y ectoparásitos que afectan a los mamíferos, las aves y a los organismos acuáticos: el PACAP, combinado con un antígeno particular, demuestra su efectividad como adyuvante al aumentar la respuesta inmunológica del huésped contra dicho antígeno; este tipo de respuesta puede observarse cuando las composiciones o combinaciones vacunales que comprenden PACAP se administran por vía oral, inyección, o por baños de inmersión en el caso de los organismos acuáticos.
MX2014002214A 2011-08-26 2012-08-24 Uso del peptido activador de la adelinato ciclasa de pituitaria como adyuvante molecular para vacunas. MX351725B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2011000167A CU24075B1 (es) 2011-08-26 2011-08-26 Composición vacunal que comprende el péptido activador de la adenilato ciclasa de pituitaria como adyuvante molecular.
PCT/CU2012/000004 WO2013029570A1 (es) 2011-08-26 2012-08-24 Uso del pacap como adyuvante molecular para vacunas

Publications (2)

Publication Number Publication Date
MX2014002214A true MX2014002214A (es) 2014-04-30
MX351725B MX351725B (es) 2017-10-25

Family

ID=47046313

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002214A MX351725B (es) 2011-08-26 2012-08-24 Uso del peptido activador de la adelinato ciclasa de pituitaria como adyuvante molecular para vacunas.

Country Status (19)

Country Link
US (1) US9549977B2 (es)
EP (1) EP2749291B1 (es)
JP (1) JP6077541B2 (es)
KR (1) KR101857705B1 (es)
CN (1) CN103874510A (es)
AU (1) AU2012303887B2 (es)
BR (1) BR112014004620B1 (es)
CA (1) CA2844898C (es)
CL (1) CL2014000386A1 (es)
CU (1) CU24075B1 (es)
ES (1) ES2648337T3 (es)
MX (1) MX351725B (es)
MY (1) MY191697A (es)
NO (1) NO2749291T3 (es)
PT (1) PT2749291T (es)
RU (1) RU2580294C2 (es)
SG (1) SG11201400215SA (es)
WO (1) WO2013029570A1 (es)
ZA (1) ZA201401271B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190060057A (ko) 2017-11-24 2019-06-03 유병희 웰빙 무드등
EP3970796A4 (en) * 2019-05-14 2022-12-21 Senju Pharmaceutical Co., Ltd. COMPOSITION FOR PREVENTING OR TREATING NEUROTROPHIC KERATITIS CONTAINING A PACAP-LIKE PEPTIDE OR A STABILIZED PACAP-LIKE PEPTIDE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE65568B1 (en) * 1990-10-22 1995-11-01 Unilever Plc Vaccine compositions for fish
RU2269354C2 (ru) * 1999-09-28 2006-02-10 Байер Корпорейшн Агонисты рецептора-3(r3) пептида-активатора гипофизарной аденилатциклазы(расар) и способы их фармакологического применения
GB0427267D0 (en) * 2004-12-13 2005-01-12 Maria Teresa De Magistris Peptide adjuvants
CU23557A1 (es) 2005-11-22 2010-07-20 Ct Ingenieria Genetica Biotech Neuropéptidos para el cultivo de organismos acuáticos
JP5908406B2 (ja) * 2009-11-02 2016-04-26 ジ アドミニストレーターズ オブ ザ トゥレーン エデュケーショナル ファンド 下垂体アデニル酸シクラーゼ活性化ポリペプチド(pacap)の類似体およびその使用方法
CN103255089B (zh) * 2013-05-03 2015-08-05 中国水产科学研究院黄海水产研究所 一株强毒迟缓爱德华氏菌疫苗株及其应用

Also Published As

Publication number Publication date
RU2014111465A (ru) 2015-10-10
SG11201400215SA (en) 2014-09-26
EP2749291A1 (en) 2014-07-02
US9549977B2 (en) 2017-01-24
CN103874510A (zh) 2014-06-18
MY191697A (en) 2022-07-07
PT2749291T (pt) 2017-11-24
JP6077541B2 (ja) 2017-02-08
ZA201401271B (en) 2015-04-29
AU2012303887A1 (en) 2014-03-06
KR20140064847A (ko) 2014-05-28
BR112014004620B1 (pt) 2019-10-29
NO2749291T3 (es) 2018-03-17
RU2580294C2 (ru) 2016-04-10
WO2013029570A1 (es) 2013-03-07
BR112014004620A2 (pt) 2017-03-21
CA2844898A1 (en) 2013-03-07
CU24075B1 (es) 2015-01-29
CL2014000386A1 (es) 2014-07-11
CA2844898C (en) 2021-06-22
ES2648337T3 (es) 2018-01-02
MX351725B (es) 2017-10-25
KR101857705B1 (ko) 2018-06-20
AU2012303887B2 (en) 2017-06-22
JP2014524450A (ja) 2014-09-22
CU20110167A7 (es) 2013-06-28
EP2749291B1 (en) 2017-10-18
US20140294889A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
MX2019008303A (es) Ácido ribonucleico modificado con nucleósidos para inducir una respuesta inmune contra el virus zika.
PH12015500092A1 (en) Compositions for immunising against staphylococcus aureus
AR069882A1 (es) Circovirus porcino, molecula de acido nucleico aislada que lo codifica, composicion inmunogenica que lo comprende, vector que comprende por lo menos una molecula de acido nucleico exogena que codifica una proteina de circovirus porcino y metodos para inmunizar un cerdo contra la infeccion virica o e
BRPI0920240B8 (pt) composição adjuvante
ECSP15011603A (es) Subunidades de vacunas de inmersión para peces
NZ602278A (en) Bluetongue virus recombinant vaccines and uses thereof
BR112016006192A2 (pt) composição de vacina de divergente de pcv2b e métodos de uso
ES2627330T3 (es) Uso de JAZ5a para mejorar la resistencia a la sequía en una planta
EA201891124A3 (ru) Новые мукозные адъюванты и системы доставки
MX344103B (es) Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle.
IN2014CN00572A (es)
PH12015501378A1 (en) Porcine parvovirus 5a, methods of use and vaccine
CO7461135A2 (es) Parvovirus porcino 5b, métodos de uso y vacuna
MY167069A (en) Antigen peptide and use thereof
MX2014002214A (es) Uso del peptido activador de la adelinato ciclasa de pituitaria como adyuvante molecular para vacunas.
WO2015144732A3 (en) Uses of parasite macrophage migration inhibitory factors
CO6362049A2 (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo
CL2014000760A1 (es) Peptido antimicrobiano aislado y purificado de branquias de tilapia (oreochromis niloticus); acido nucleico que lo codifica; composicion que lo comprende; y su uso para el control de patogenos y como adyuvante molecular en una composicion vacunal para aumentar la respuesta inmune contra el antigeno vacunal.
RU2015125699A (ru) Антигены и комбинации антигенов pseudomonas
CL2015003616A1 (es) Cepa de piscirickettsia salmonis depositada bajo el numero de registro dms 27338; vacuna que la comprende; uso para prevenir infeccion por p. salmonis; y medio de cultivo para p. salmonis.
WO2015048785A3 (en) Mosaic conserved region hiv immunogenic polypeptides
EA201401044A1 (ru) Модифицированный вирус болезни марека и вакцины на его основе
ES2441880B1 (es) Composición basada en polipéptidos para el tratamiento de miasis
CU24473B1 (es) Composición vacunal que comprende un péptido secretagogo de la hormona de crecimiento como adyuvante vacunal
TH151450A (th) การใช้ของ pacap ในรูปโมเลกุลสารเสริมฤทธิ์สำหรับวัคซีน

Legal Events

Date Code Title Description
FG Grant or registration